- Arnold Snider, Chairman of the Board.Director at Christopher Reeve Paralysis Foundation
- Joseph Loscalzo, M.D., PhDHarvard Medical School
- Howard Furst, M.D.Deerfield Management
- Michael TreismanTiger Management
- Charles Scoggin, M.D.CEO N30 Pharmaceuticals
Arnold Snider
Mr. Arnold Snider serves as the Chairman of the Board and Director of N30 Pharmaceuticals.
Mr. Snider was the Founder of Deerfield Management Company L.P. and served as its General Partner. Prior to Deerfield, Mr. Snider served as a Pharmaceutical Analyst at Kidder, Peabody & Co. for 17 years and also worked at Tiger Management.
Mr. Snider started two foundations to benefit Lupus Research – Rheuminations, Inc. and the Lupus Clinical Trials Consortium.
Mr. Snider serves as a Director at Christopher Reeve Paralysis Foundation and Christopher and Dana Reeve Foundation and also serves as a Trustee of Davidson College.
Mr. Snider received his MBA from Davidson College.
Joseph Loscalzo, M.D., PhD
Hersey Professor of the Theory and Practice of Medicine Harvard Medical School,
Physician-in-Chief Brigham and Woman’s Hospital,
Editor-in-Chief Circulation
Dr. Joseph Loscalzo is a Director and Chairman of the Scientific Advisory Board of N30 Pharmaceuticals.
Dr. Loscalzo was the Co-Founder, Director, and Chairman of the Scientific Advisory Board of NitroMed, Inc. He is a Member of the Scientific Advisory Board at CB Health Ventures, L.L.C., Excel Medical Ventures, and Mi3 Ventures Partners. He also served as a Member of the Scientific and Clinical Advisory Committee of Adherex Technologies Inc.
Dr. Loscalzo is the Wade Professor and Professor of Biochemistry, Chairman of the Department of Medicine since 1997, and Director of the Whitaker Cardiovascular Institute at Boston University School of Medicine. He joined the faculty of Boston University in 1994 as Chief of Cardiology. Dr. Loscalzo is also the Physician-in-Chief at Boston Medical Center.
In 2004, Dr. Loscalzo became Editor-in-Chief of Circulation. Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He ultimately rose to the rank of Associate Professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and Director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital.
Dr. Loscalzo is a Director of the Whitaker Cardiovascular Institute at Boston University School of Medicine. He is a Director of the NIH-sponsored Specialized Center for Research in Ischemic Heart Disease at Boston University and the Chairman of the Executive Committee of the NIH-sponsored Cardiovascular Proteomics Center at Boston University.
Dr. Loscalzo has served on several NIH study sections and editorial boards, including serving as past Associate Editor of the New England Journal of Medicine and has chaired the Gordon Conference on Thrombolysis. Dr. Loscalzo is the immediate past Chair of the Cardiovascular Board of the American Board of Internal Medicine and immediate past Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the NIH.
Dr. Loscalzo has authored and co-authored more than 400 scientific publications and 20 books. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, and atherosclerosis over the past 20 years.
Dr. Loscalzo has received many awards including the Clinician-Scientist Award and the Distinguished Scientist Award of the American Heart Association, the Research Career Development Award of the NIH, the George W. Thorn Award for Excellence in Teaching at Brigham and Women’s Hospital, Educator of the Year Award in Clinical Medicine at Boston University, the Glaxo Cardiovascular Research Award, and election to the prestigious American Society for Clinical Investigation and Association of American Physicians.
Dr. Loscalzo’s training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiology. Dr. Loscalzo received a Ph.D. in Biochemistry, a M.D. from the University of Pennsylvania, and an A.B. degree, summa cum laude.
Howard Furst, M.D.
Deerfield Management
Dr. Howard Furst serves on the board of N30 Pharmaceuticals.
Dr. Furst was a Managing Director at Maverick Capital, an Investment Firm. From January 2000 to March 2006, Dr. Furst served in various positions at Maverick Capital, including Principal since January 2005. Dr. Furst served as an Independent Director of Perlegen Sciences, Inc., since January 2004.
From 1997 to 2000, Dr. Furst served a Fellow in the University of Pennsylvania’s Renal Electrolyte and Hypertension Division. Dr. Furst served as Senior Chief Medical Resident of New York University from 1996 to 1997.
Dr. Furst holds a B.A. in Biological Basis of Behavior, an M.B.A. from the University of Pennsylvania and an M.D. from New York University.
Michael Treisman
General Counsel, Tiger Management
Mr. Michael Treisman serves on the board of N30 Pharmaceuticals and is General Counsel for Tiger Management.
Prior to joining Tiger Management, Mr. Treisman held numerous legal positions within Citi Alternative Investments, the alternative investments platform for Citigroup Inc., and spent several years as a lawyer with Cleary Gottlieb Steen & Hamilton LLP.
Mr. Treisman graduated from Choate Rosemary Hall in 1990 and the University of Pennsylvania in 1994. He then spent several years working as a legislative assistant to U.S. Congressman Barney Frank and as a staff member on the Subcommittee on International Development, Finance, Trade and Monetary Policy of the U.S. House of Representatives Committee on Financial Services.
In 2000, Mr. Treisman graduated from the Duke University School of Law and subsequently served as a clerk to the Honorable Anthony Scirica on the U.S. Court of Appeals for the Third Circuit. Mr. Treisman is currently on the Steering Committee for the Ron Brown Scholar Program.
Charles Scoggin, M.D.
CEO N30 Pharmaceuticals
Dr. Charles Scoggin has been CEO of N30 Pharmaceuticals since its founding in 2007.
Prior to entering the private sector, Dr. Scoggin was Professor of Medicine (with tenure) at the University of Colorado. Since that time, Dr. Scoggin has served as CEO of private and public biomedical companies.
Dr. Scoggin trained in internal medicine at Duke University and pulmonary and critical care medicine at the University of Colorado, and was a Senior Scientist at the Eleanor Roosevelt Institute.
During his academic career, Dr. Scoggin received numerous awards and recognitions. He was Teaching and Research Scholar of the American College of Physicians, a Fellow of the American College of Physicians, Research Scholar of the American Lung Association, and Fellow of the American College of Chest Physicians.
Dr. Scoggin has authored over 100 scientific articles, book chapters, and abstracts. These articles have been published in peer review journals, including: The New England Journal of Medicine, Journal of the American Medical Association, Proceedings of the National Academy of Sciences, American Journal of Human Genetics, Journal of Molecular and Somatic Cell Genetics, Chest, and the American Journal of Respiratory and Critical Care Medicine.